Tags

Type your tag names separated by a space and hit enter

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.
Vaccine. 2010 Oct 21; 28(45):7331-6.V

Abstract

We reviewed the safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents (aged 6 months-18 years) in an integrated analysis of all pediatric trials evaluating MF59-containing influenza vaccines completed to date (5 trials). In the MF59-adjuvanted group (n=1181) versus the non-adjuvanted group (n=545) there was no increase in the incidence of unsolicited adverse events and serious adverse events. As expected, solicited local or systemic reactions occurred more frequently in MF59-adjuvanted subjects; however, a majority of reactions were mild and transient. These data support the safety of MF59-adjuvanted influenza vaccines in the pediatric population.

Authors+Show Affiliations

Center for Global Health and Division of Infectious Diseases, Cincinnati Children's Hospital, 3333 Burnet Ave, Cincinnati, OH 45326, USA. stevblack@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20813217

Citation

Black, Steven, et al. "Safety of MF59-adjuvanted Versus Non-adjuvanted Influenza Vaccines in Children and Adolescents: an Integrated Analysis." Vaccine, vol. 28, no. 45, 2010, pp. 7331-6.
Black S, Della Cioppa G, Malfroot A, et al. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine. 2010;28(45):7331-6.
Black, S., Della Cioppa, G., Malfroot, A., Nacci, P., Nicolay, U., Pellegrini, M., Sokal, E., & Vertruyen, A. (2010). Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine, 28(45), 7331-6. https://doi.org/10.1016/j.vaccine.2010.08.075
Black S, et al. Safety of MF59-adjuvanted Versus Non-adjuvanted Influenza Vaccines in Children and Adolescents: an Integrated Analysis. Vaccine. 2010 Oct 21;28(45):7331-6. PubMed PMID: 20813217.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. AU - Black,Steven, AU - Della Cioppa,Giovanni, AU - Malfroot,Anne, AU - Nacci,Pantaleo, AU - Nicolay,Uwe, AU - Pellegrini,Michele, AU - Sokal,Etienne, AU - Vertruyen,André, Y1 - 2010/09/15/ PY - 2010/03/25/received PY - 2010/08/11/revised PY - 2010/08/16/accepted PY - 2010/9/4/entrez PY - 2010/9/4/pubmed PY - 2011/1/25/medline SP - 7331 EP - 6 JF - Vaccine JO - Vaccine VL - 28 IS - 45 N2 - We reviewed the safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents (aged 6 months-18 years) in an integrated analysis of all pediatric trials evaluating MF59-containing influenza vaccines completed to date (5 trials). In the MF59-adjuvanted group (n=1181) versus the non-adjuvanted group (n=545) there was no increase in the incidence of unsolicited adverse events and serious adverse events. As expected, solicited local or systemic reactions occurred more frequently in MF59-adjuvanted subjects; however, a majority of reactions were mild and transient. These data support the safety of MF59-adjuvanted influenza vaccines in the pediatric population. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/20813217/Safety_of_MF59_adjuvanted_versus_non_adjuvanted_influenza_vaccines_in_children_and_adolescents:_an_integrated_analysis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(10)01245-4 DB - PRIME DP - Unbound Medicine ER -